Hualan Biological Vaccine 301207.SZ · CNY

Its shares trade on Shenzhen under the ticker 301207.SZ. It has been listed since 18 February 2022. In the fiscal year to 31 December 2025, it reported revenue of CN¥1.20bn and net income of CN¥182.9m. At that date it held total assets of CN¥6.84bn and shareholders' equity of CN¥5.70bn.

Hualan Biological Bacterin Inc. engages in vaccine and related medical supplies production. The company is headquartered in Xinxiang, Henan. The company went IPO on 2022-02-18. The firm's listed products mainly include influenza virus split vaccine, quadrivalent influenza virus split vaccine, influenza A H1N1 split vaccine, recombinant hepatitis B vaccine and others. The firm's products that have been approved for clinical trials or have passed clinical registration and are pending for marketing mainly include human rabies vaccines, adsorbed tetanus vaccines, H7N9 influenza whole virus inactivated vaccines and others. The firm's products in the preclinical research stage include inactivated new coronavirus vaccine, freeze-dried nasal spray recombinant new coronavirus live attenuated vaccine and others.

Figures and description from our data supplier, not checked against the company's own report.

• Mr. Kang AnChairman of the Board, since 2005
• Ms. Wenjue AnActing Chief Financial Officer, General Manager, Acting Secretary of the Board, Director, since 2020CN¥263,300
• Ms. Ruowen PanExecutive Deputy General Manager, Director, since 2020CN¥601,200
• Ms. Wenqi AnDirectorCN¥167,900
• Ms. Bei FanDirector
• Mr. Xiaowei MaDirector
• Mr. Dexin LiIndependent DirectorCN¥100,000
• Mr. Dongsheng YangIndependent DirectorCN¥100,000
• Mr. Jingang ZhangIndependent Director

Overall

0

Environment

0

Social

0

Governance

0

Data on this tab

Our data supplier

Chart on the Overview

TradingView

Nothing here is investment advice. Prices can be delayed or wrong, so check with the exchange before relying on them. Data for this page. How we cover markets.